M.A. Azerad Archives

BHS clinical guidelines on the management of acute complications in sickle cell disease

BJH - volume 10, issue 4, june 2019

T. van Genechten MD, A. Vanderfaeillie MD, M.A. Azerad MD, D. Kieffer PhD, PharmD, V. Labarque MD, PhD, B. Gulbis MD, PhD, A. Ferster MD, PhD, B. De Wilde MD, PhD

With the increasing prevalence of sickle cell disease patients in Western countries, it is of importance to improve awareness among medical doctors of its complications. To reduce long-term morbidity and mortality, the prompt recognition and treatment of acute complications is important. The existing clinical guideline ‘Follow-up and treatment of patients with sickle cell disease hospitalised for Vaso Occlusive Crisis or infection’, published in 2012 by the Belgian Haematological Society, was revisited to better suit the practical needs of first-line practitioners.

(BELG J HEMATOL 2019;10(4):165–8)

PP2.5 Hypercoagulability in adult sickle cell patients as compared to sickle cell trait subjects and a control group

BJH - volume 7, issue Abstract Book BHS, january 2016

B. Mahadeb , D. Noubouossie MD, L. Rozen PharmD, T. Besse-Hamme , A. Efira MD, P. Hermans MD, PhD, B. Gulbis MD, PhD, M.A. Azerad MD, A. Demulder MD, PhD

Thrombin generation in the plasma of sickle cell trait adults shows prothrombotic profile as compared to normal adults

BJH - 2014, issue Abstract Book BSTH, november 2014

L. Dewispelaere MD, B. Mahadeb , L. Rozen PharmD, D. Noubouossie MD, T. Besse-Hamer , A. Efira MD, P. Hermans MD, PhD, B. Gulbis MD, PhD, M.A. Azerad MD, A. Demulder MD, PhD

Microvesicles and cancer

BJH - volume 4, issue 1, march 2013

M.A. Azerad MD, F. Debaugnies PharmD, A. Demulder MD, PhD, D. Bron MD, PhD, A. Efira MD

Summary

Microvesicles (MV) are since quite recently recognized as forming a unique network between cells. These very little fragments (<1 µm size) are actively released from their parent cells and are able to transfer both cellular and nuclear material. Although active debate remains on how to best detect MV, rendering some results questionable, high MV levels have been reported in aggressive tumours and have been correlated with a poor clinical outcome. Some tumour cell derived MV exhibit strong tissue factor dependent procoagulant activity. Their detection could actually predict the thrombotic risk in selected cancer patients. A growing body of evidence suggests cell microvesicles to be a major link between cancer and thrombosis. Current knowledge on MV in cancer will be reviewed here.

(BELG J HEMATOL 2013;1:3–8)